Directory · FR
Biotechnology Research in France
A register of firms and the professionals working at them in the Biotechnology Research sector based in France. Browse the public index, then filter or export on Kipplo.
Companies
1.3K on file
Cellectis
Cellectis is a global clinical-stage biopharmaceutical company. Pioneers and innovators in our field, our mission is to develop innovative treatments for patients with unmet medical needs. With 25 years of expertise, we have the best-in-class gene editing platform focusing on immuno-oncology, and gene therapy. Through our efficient and precise TALEN® technology, we create allogeneic CAR-T cells capable of recognizing and combating cancer cells. Today, our two* clinical programs target patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) and non-Hodgkin lymphoma (NHL). We are fully integrated and a leader in end-to-end gene editing, allogeneic CAR T-cell companies. With our in-house manufacturing, we control our gene and cell therapy process from start to finish with starting materials produced in Paris (France) and CAR-T therapy products created in Raleigh, NC. We also have several ongoing strong collaborations, based on our TALEN® technology, with leading cell & gene therapy companies, including our recent partnership with AstraZeneca, to develop new product candidates in oncology, immunology, and treatment of rare diseases. At Cellectis, we are committed to a cure. Cellectis headquarters are in Paris, France, with additional locations in New York, New York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). To find out more about us, visit our website: To learn more about our community guidelines, visit: Follow our other social media account on X.(*) On November 4, 2024, Cellectis decided to focus its current development efforts on the BALLI-01 and NATHALI-01 studies and therefore to deprioritize the development of UCART123. TALEN® is a registered trademark owned by the Cellectis Group.
51 to 200 staff
Treefrog Therapeutics
TreeFrog Therapeutics is a French-based biotech company aiming to unlock access to cell therapies for millions of patients. TreeFrog Therapeutics is developing a pipeline of therapeutic candidates using proprietary C-Stem technology, allowing for the mass production of induced pluripotent stem cells and their differentiation into ready-to-transplant microtissues with unprecedented scalability and cell quality. Bringing together over 150 biophysicists, cell biologists and bioproduction engineers, TreeFrog Therapeutics raised $82M in 2021 to advance its pipeline of stem cell-based therapies in the field of regenerative medicine with the lead program in Parkinson's Disease. In 2022, the company opened a technological hub in Boston, USA to drive the adoption of C-Stem and initiate co-development partnerships with leading academic, biotech and industry players in the field of cell therapy.
51 to 200 staff
Bioaster
BIOASTER Technology Research Institute (TRI) is working to develop an unique technological and innovative model to support the latest challenges in microbiology, in particular to -Fight antimicrobials resistance-Improve vaccines safety and efficacy-Quickly diagnose infections at patient bedside-take full advantage to human and animal microbiota. In order to overcome technological bottlenecks and explore new avenues, BIOASTER is leading collaborative projects that bring together academics, start-ups, SMEs and industrial groups around key thematic and technology units. Each project strives on academic research excellence and is undertaken by a team of high-level experts and engineers, which benefits from state-of-the-art equipment, technological infrastructures. BIOASTER, an independent non-profit organization, is one of 8 French TRIs created in 2012 on the initiative of the French Government through the “Investments for the Future” program. The two historical founders are Lyonbiopôle (a biocluster, the one-stop shop for healthcare innovation in Rhône-Alpes, France) and the Institut Pasteur in Paris. They were joined from the beginning by the CNRS, the INSERM, the CEA, Mérieux Institute, Danone Nutricia Research and Sanofi Pasteur -and newly joined by bioMérieux- to create a unique Technology Institute dedicated to infectious diseases and microbiology in health. The Institute benefits from the support of Lyon Métropole and the Region Auvergne Rhône Alpes and the dynamism of a group of 40 SMEs in the Lyon and Paris regions. Located in Lyon and Paris, BIOASTER has more than 100 employees including 80 world-class scientists and engineers originating from 16 different countries. More information on
51 to 200 staff
Biosynex Pharma
BIOSYNEX conçoit, fabrique et commercialise des solutions de diagnostic rapide pour une santé accessible, préventive et personnalisée. Le groupe développe également des marques à forte notoriété dans l’univers du bien-être et de la santé, telles qu’INNOXA, experte du soin oculaire et dermo-cosmétique, et PARAKITO, spécialiste des solutions anti-nuisibles. Fondé en 2005, le groupe vend ses produits et solutions en France et dans plus de 90 pays dans le monde entier.
501 to 1000 staff
Carbios
CARBIOS is a biotech company developing and industrializing biological solutions to reinvent the life cycle of plastic and textiles. Inspired by nature, CARBIOS develops enzyme-based processes to break down plastic with a mission to avoid plastic and textile pollution and accelerate the transition to a circular economy. Its two disruptive technologies for the biorecycling of PET and the biodegradation of PLA are reaching industrial and commercial scale. Its biorecycling demonstration plant has been operational since 2021 and construction work of the world’s first industrial biorecycling plant is expected to restart between June and September 2025, subject to the necessary additional funding. CARBIOS, founded by Truffle Capital, has received scientific recognition, notably with the cover of Nature and a second article published by Nature, and is supported by prestigious brands in the cosmetics, Food & Beverage and apparel industries to enhance their products’ recyclability and circularity. Nestlé Waters, PepsiCo and Suntory Beverage & Food Europe are members of a packaging consortium founded by CARBIOS and L’Oréal. On, Patagonia, PUMA, PVH Corp. and Salomon collaborate with CARBIOS in a textile consortium. CARBIOS is part of the B Corp™ global community of companies using business as a force for good.
51 to 200 staff
Dna Script
DNA Script was created to revolutionize DNA synthesis with enzymes. Our core R&D efforts have produced innovations in enzyme engineering, surface and nucleotide chemistries, and instrumentation. The integration of these innovations has resulted in SYNTAX™, the world’s first benchtop DNA printer powered by enzymatic technology. With continued advancement and innovation, we believe DNA Script’s enzymatic DNA synthesis technology is poised to become the engine of genomics research and personalized medicine.
51 to 200 staff
Genoway
Since genOway aims at bridging the gap between preclinical findings and clinical success with advanced, genetically engineered preclinical models and solutions. From customized mice and rats to ready-to-use cell lines, our solutions provide increased predictability and accelerate therapeutic breakthroughs. We work with 17 of the world’s Top pharma companies—as well as leading biotech firms, CROs, and academic institutions. At the heart of genOway is a team of 150+ skilled professionals, from 17 nationalities, all committed to advancing preclinical research. What We Offer • A catalogue of validated, ready-to-use mice and cell lines—developed in partnership with biopharma leaders • Custom-made models tailored to specific research goals • Proof-of-concept experiments aligned with model design and project needs What Makes Us Unique • Scientific Excellence: Our models have contributed to peer-reviewed publications and IND approvals. • Easy access to the models: High-health-status models sourced from certified breeders in the US and Europe • Strong Collaborations: Models co-validated with pharma and biotech partners • Full Freedom to Operate: Secure use of technologies with guaranteed FTO in the specific field Our Commitment to Sustainability Through the genOway Low-Carbon Project, launched in 2021, we’ve committed to reducing our greenhouse gas emissions by 6% annually over a period of 5 years, by rethinking lab operations, logistics, and energy use. We’re proud to report that this initiative has already delivered measurable results, putting us on track to meet our reduction targets.
51 to 200 staff
Innovative Diagnostics
Since 2004, Innovative Diagnostics (ID) develops, produces and sells ELISA, PCR and rapid tests to diagnose infectious zoonotic and veterinary diseases. Over 130 employees work in our m² headquarters at the heart of the “MED Valley” of Montpellier, France. ID has shown continuous growth over the years and offers a wide range of veterinary tests sold in over 100 countries under the brand name IDvet. ID is an actor of the One Health approach, which recognizes that human and animal health are interdependent. We contribute to securing the global health and food supply, thanks to the control of zoonotic and veterinary diseases. Further to the emergence of COVID-19, we quickly developed COVID-19 ELISA tests detecting IgG, IgA and IgM in sera, and an immunochromatographic test for nasopharyngeal swabs. “With you at every step” is our motto. To improve global supply and assistance, we have a training center in Jordan, offices in Brazil, India, China, and a production facility in the USA. In 2016, we contributed to creating ID Solutions to provide tools to detect oncogenic mutations in human circulating DNA by dPCR. When COVID-19 emerged, ID made its know-how, industrial infrastructures, staff and financial resources available to ID Solutions in order to develop and produce COVID-19 PCR kits for use in humans, allowing ID Solutions to become a major COVID PCR kit manufacturer in France. ID left ID Solutions presidency in December 2021 and sold all its shares in May 2022. ID Solutions is now fully independent and heading for their new own projects. In 2021, ID contributed to the creation of DI4diag: “Deep Intelligence for diagnostics”. This company gathers talents from Montpellier University and the industry. It aims to provide easy-to-use and affordable diagnostics for syndromic infectious diseases, thanks to technologies that combine molecular technics and artificial intelligence. These testing tools will be particularly useful for LMIC.
51 to 200 staff
Inserm Transfert
Inserm Transfert is the Inserm subsidiary dedicated to value creation and technology transfert in lifescience and human health. Inserm Transfert, the private subsidiary of the French National Institute of the Health and Medical Research (Inserm), is responsible for value creation of Inserm innovations in human health and promotes long-term technology transfers in line with international best practices. Inserm Transfert SA was founded in and manages, under a Public Service Management Contract (Délégation de Service Public), the entire promotion and transfer of knowledge emerging from the Inserm research laboratories to the industrial world, from invention disclosure to industrial partnerships and startups incorporation. Inserm Transfert also offers services relating to setting up and managing national, European and international projects, as well as supporting the technology transfer of clinical research and health data/databases. In 2009, Inserm Transfert and Inserm established an investment fund to finance proofs of concept. In 2005, Inserm Transfert Initiative, a dedicated seed money fund for life sciences, was created. Since 2017 a pathway for pre-entrepreneurship supports researchers/inventors that aspire to become involved in entrepreneurship.
51 to 200 staff
Silab
SILAB is an independent French company specializing in research and development, production and commercialization of natural active ingredients for the international cosmetic and dermo-cosmetic markets. With more than 400 employees in France and abroad, and continuous investment in People and innovation, SILAB is one of the world leader in its field for more than 35 years, with 4 to 6 products launched each year. SILAB relies on its sales subsidiaries (USA, China, Brazil, Singapore, South Korea) and on its network of exclusive distributors to generate 60% of sales in exports. The company embedded its strategy on strong founding values - Independence, Excellence and Quality - and pursues its development devoted to its clients and its committed teams in the respect of SILAB’s beliefs to sustainable development detailed in its Actively Caring CSR program.
201 to 500 staff
Discngine
Discngine is a leading developer and provider of scientific software for Life Science Research organizations. Founded in 2004 and based in Paris, Discngine is dedicated to enhancing the discovery of new molecules. Its in-house developed SaaS applications and tailored IT solutions support R&D divisions across the pharmaceutical, cosmetics, and agro-sciences industries worldwide. Discngine’s expertise spans cheminformatics, structural bioinformatics, lab informatics, and data science. Coupled with in-depth knowledge of molecular modeling and simulation, as well as experimental data acquisition and management, Discngine delivers cloud-based applications that comply with ISO-27001 information security management standards. Discngine has over 75 employees worldwide and recently shifted to a distributed model. Thanks to its strong company culture and innovative management, Discngine offers a friendly and exciting working environment to everyone who wants to join the company!
51 to 200 staff
Transcure Bioservices
TransCure bioServices, a Taconic Biosciences company Rethinking preclinical research with your goals in mind. TransCure bioServices accelerates drug development by delivering the right humanized models, the right data, and the right partnership mindset. As part of Taconic Biosciences, a global leader in genetically engineered and humanized mouse models, we offer a fully integrated translational research platform, combining world-class models with advanced in vivo preclinical services. Our humanized mouse platforms generate robust, translatable in vivo data to support critical decision-making in- Oncology (Human CDX, Human PDX, Syngeneic Models)- Inflammatory diseases (IBD, MASH, GvHD, Lung Inflammation)- Infectious diseases & toxicity (HIV, HBV, Immunotoxicity, Hepatotoxicity) Every study is co-designed with your team to align with your scientific strategy, timelines, and regulatory requirements - keeping you in control, while we manage the complexity. Based in France (near Geneva), our BSL-2 and BSL-3 facilities, combined with highly experienced scientific teams, ensure the highest standards of quality, safety, and animal welfare. With over 12 years of expertise and hundreds of completed studies, TransCure bioServices proudly supports biotech, pharma, and academic partners worldwide from early discovery to clinical readiness.
51 to 200 staff
Adocia
Innovative medicine for everyone, everywhere" Listed on the Euronext stock market, Adocia is a clinical-stage biotech company specialized in the development of best-in-class medicine relying on innovative formulations of already-approved therapeutic proteins. Adocia is specialized in diabetes and obesity. The proprietary BioChaperone® technological platform is designed to enhance the effectiveness and safety of therapeutic proteins and their ease of use for patients. For more information, visit our website: For careers offers, please click to the following link :
51 to 200 staff
Biowest
Biowest SAS (Biowest) is the European leader in the collection and processing of animal sera and cell culture media, offering the widest range of sera and media available on the market. Biowest controls the production of the sera throughout the entire process, from collections around the world to final shipment of bottled serum from its warehouse. Biowest offers standard cell culture media as well as custom-made formulations for specific applications, using its outstanding knowledge of cell culture products. Biowest can also offer highest quality and premium service, ability to address special requirements and full traceability and security guaranteed by vertical integration. Founded in 1987, Biowest has since 2004 been a member of the Viking/Serascandia group, collectors of animal by-products in Latin America; thus becoming the first serum company vertically integrated from raw material to finished product.
11 to 50 staff
Genethon
Généthon est un laboratoire à but non lucratif, créé et soutenu par l’AFM-Téléthon depuis 1990. Après avoir été précurseur du déchiffrage du génome humain et de l’identification de gènes responsables des maladies génétiques, notre mission est de concevoir et de développer des traitements de thérapie génique pour des maladies rares (maladies neuromusculaires, déficits immunitaires, maladies du sang, du foie et de la vision). Plus de 240 chercheurs, médecins, pharmaciens, ingénieurs, techniciens de laboratoire et autres experts œuvrent avec audace et conviction pour relever les défis scientifiques, technologiques et cliniques. Basé à Évry-Courcouronnes, au cœur d’un pôle d’excellence en biothérapies, Généthon incarne un modèle unique au monde alliant recherche académique, innovation technologique et engagement associatif.
201 to 500 staff
Genopole
Created in 1998, Genopole® has a threefold mission- develop a high-level research campus in genomics and post-genomics, focused on gene therapy in collaboration with the University Evry-Paris Saclay- encourage the start-up and foster the development of biotech companies in the Paris region by providing personalized advice and support, including financial assistance - create a biopark in Evry-Courcouronnes in collaboration with the research campus.
11 to 50 staff
I-Sep
Fondée en 2015 à Nantes, i-SEP est une medtech spécialisée dans l'autotransfusion peropératoire et la gestion du sang des patients. Chez i-SEP, nous avons développé, breveté et commercialisons désormais une technologie innovante de récupération et de séparation des composants sanguins. En collaboration avec nos cliniciens, nous développons des solutions uniques de gestion du sang des patients pour améliorer les avantages pour les patients et les parties prenantes. Nous travaillons en étroite collaboration avec des cliniciens spécialisés dans le but d’améliorer les avantages pour les patients, de simplifier le flux de travail des médecins et de contribuer à réduire les coûts des soins de santé. Notre innovation apporte une valeur ajoutée significative par rapport aux solutions actuellement disponibles, notamment en termes de qualité du sang. i-SEP a été co-fondée par trois associés : Dr Francis Gadrat, médecin anesthésiste, Bertrand Chastenet, ancien chef d’entreprise et consultant dans l'industrie pharmaceutique, conseiller du commerce extérieur de la France, et Sylvain Picot, fondateur de Biom’Up. i-SEP est accompagnée par Atlanpole et membre du pôle de compétitivité Atlanpole Biothérapies- Founded in 2015 in Nantes (Upper Britany, France), i-SEP is a medtech specialized in intraoperative autotransfusion and Patient Blood Management. At i-SEP, we have developed, patented and now markets an innovative technology for the recovery and separation of blood components. Together with our clinicians, we develop unique Patient Blood Management solutions for improved patient & stakeholder benefits. We work closely with specialized clinicians with the aim of improving patient benefits, simplifying physicians’ workflow and helping reduce healthcare cost. Our innovation brings significant added value compared to currently available solutions, particularly in terms of blood quality.
11 to 50 staff
Igem
iGEM is dedicated to advancing achievements in synthetic biology through education and competition, and to the development of an open, collaborative and cooperative community that strives to find solutions for a healthier, more resilient and sustainable world. Held annually in Paris, iGEM’s flagship event is the Grand Jamboree. This event marks the culmination of iGEM’s yearly activities, bringing together the global members of all iGEM Programs: the iGEM Competition, iGEM Startups, iGEM Responsibility, iGEM Community and iGEM Technology. The Grand Jamboree also assembles researchers, industry reps, startup founders, investors, journalists, experts in governance and policy, and the general public to help chart the future of synthetic biology. Why not come witness the future and interact with tomorrow's synbio leaders? Hope to see you soon!
11 to 50 staff
Janvier Labs
The culture of excellence to support research and to improve tomorrow's health.
201 to 500 staff
Netri
NETRI is an Techbio industrial start-up whose mission is to improve human health through the discriminating power of the nervous system. The company offers a Neuron-as-a-sensor suite (NaaS) to gain insights into the safety and efficacy of clinical or chemical compounds. NETRI focuses on pain quantification and pursues an exploratory pipeline in oncology-related adverse events, dermo-cosmetics, neurological disorders and neurotoxicity. Leveraging the natural capacity of neurons to encode biological interactions into electrical impulses, the NaaS suite features the world-first compartmentalized electrophysiology platform in standard 96-well plate format - NeuroFluidics™ MEA - which acts as a data generation hub for its digital signature libraries of tested and reference compounds. To enable the prediction of clinical outcomes, the proprietary suite includes calibrated neuronal cells, Organ-on-chip hardware, AI-trained software, digital libraries and methods.
11 to 50 staff
Novalix
Novalix is a premier drug discovery partner to biotech firms and pharmaceutical companies. We apply our exceptional scientific talent and exclusive resources across our platforms to improve the odds of success at each critical pre-clinical stage. The better the science, the better the outcomes. For additional information visit
201 to 500 staff
Oz Biosciences
OZ Biosciences is a product development company that creates, develops and commercializes delivery systems of bioactive materials (DNA, siRNA, proteins, antibodies.), intended for the worldwide scientific community and pharmaceutical industries. Our mission is to assist scientists to accelerate the rhythm of discoveries by offering them technologically advanced tools such as transfection reagents and other life science research products. Principal innovations are based on proprietary technologies such as Magnetofection (magnetic-assisted transfection or infection), Magneto-Biolistic, transfection reagents, transduction tools, mRNA and lipids-based delivery systems (LNP). Specialized and expert in drug delivery systems, we also provide custom transfection, mRNA and LNP services and are involved in many international research projects. For more info, please contact: contact@ozbiosciences.com or contactusa@ozbiosciences.com (North America).
11 to 50 staff
Polaris
POLARIS, expert in innovative nutritional lipids, offers a range of health ingredients and high-valued custom manufacturing activity. POLARIS is specialized in production and formulation of Polyunsaturated Fatty Acids especially Omega-3 from marine and algal origin under the brand Omegavie.
11 to 50 staff
Proteogenix
ProteoGenix is a leading life sciences organization which provides services in molecular biology and immunology and in particular polyclonal and monoclonal antibody development, recombinant protein expression and purification, peptide synthesis as well as gene synthesis. ProteoGenix’s commitment to its clients is to ensure the access to comprehensive and integrated solutions to help our customers develop the tools they need to efficiently conduct their biology and research projects in a time effective manner. Beginning with the synthesis of the gene ProteoGenix develops all the materials required for immunoassay services. Proteogenix’s exceptional and functional expertise combined with our extensive scientific knowledge and experience ensures ProteoGenix to be a reliable partner for your antibodies, proteins, genes (cDNA) and peptides. Our custom services ensure a unique and tailored process to our clients revolving around four areas : Protein expression and purification in E. Coli, Yeast, Insect cells (baculovirus) and Mammalian Cells Monoclonal antibody production and Polyclonal antibody production Gene synthesis, sub-cloning and mutagenesis Peptide synthesis, purification and conjugation ProteoGenix also provides the research and academic communities with a wide range of commercial products available on our website such as antibodies, proteins, ELISA kits, tissue microarrays, chimera RNAi, molecular biology products as well as many more.
11 to 50 staff
